A Passage to optimal CNS vectors
Passage uses James Wilson’s AAV vectors, gene therapies targeting the CNS
Passage is arming itself with AAV vectors, gene therapies and non-human primate studies from gene therapy pioneer James Wilson at UPenn to develop disease-modifying treatments for rare monogenic diseases affecting the CNS. The company launched last month with a $115.5 million series A round led by OrbiMed Advisors.
Passage Bio Inc. co-founder and interim CEO Stephen Squinto told BioCentury that most other companies in